Common Stock, $0.16 par value per share
- Symbol
- NEOG
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01 · 8-K
Neogen Corporation
NEOGNASDAQEQUITYCurrent
Other Events
Item 8.01 Other Events. On March 2, 2026, Neogen Corporation (“Neogen”) announced that it had entered into a definitive agreement to sell its global Genomics business to Zoetis Inc. (“Zoetis”). This transaction is subject to customary closing conditions and regulatory approvals.…
Company context
Neogen Corporation is committed to fueling a brighter future for global food security through the advancement of human and animal well-being. Harnessing the power of science and technology, Neogen has developed comprehensive solutions spanning the Food Safety, Livestock, and Pet Health & Wellness markets. A world leader in these fields, Neogen has a presence in over 140 countries with a dedicated network of scientists and technical experts focused on delivering optimized products and technology for its customers.
Current securities
Historical securities (1)
Registered securities in this filing
Neogen Corporation · 8-K · Filed 2026-11-04
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events.
On March 2, 2026, Neogen Corporation (“Neogen”) announced that it had entered into a definitive agreement to sell its global Genomics business to Zoetis Inc. (“Zoetis”). This transaction is subject to customary closing conditions and regulatory approvals. Both parties continue to cooperate with the Australian Competition and Consumer Commission (the “ACCC”) and the New Zealand Commerce Commission (the “NZCC”) in their ongoing reviews of the transaction. In order to assist the regulatory clearance process Zoetis has recently offered to divest certain assets in Australia, and as a result we expect regulatory review to conclude in early 2027.